Treatment Options for KRASG12C Mutated NSCLC

Opinion
Video

Dr Narjust Florez outlines FDA-approved firstline therapy options for KRAS G12C mutated non-small cell lung cancer, and notes most patients progress and require second line targeted therapy.

Recent Videos
6 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
Related Content
Neoadjuvant Nivolumab/Chemo Improves OS Vs Chemotherapy in Resectable NSCLC

Neoadjuvant Nivolumab/Chemo Improves OS Vs Chemotherapy in Resectable NSCLC

Tim Cortese
February 19th 2025
Article

Updated, comprehensive OS results with the combination in resectable NSCLC will be shared in a future peer-reviewed setting.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

FDA Grants Fast Track Designation to IBI363 in Pretreated Squamous NSCLC

FDA Grants Fast Track Designation to IBI363 in Pretreated Squamous NSCLC

Tim Cortese
February 17th 2025
Article

IBI363 demonstrated encouraging efficacy and a manageable safety profile in patients with squamous NSCLC based on results from a phase 1 trial.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Radiotherapy plus camrelizumab and platinum-doublet chemotherapy showed manageable toxicity in untreated non–small cell lung cancer with brain metastases.

Radiation Combo Elicits Efficacy in Advanced NSCLC With Brain Metastases

Roman Fabbricatore
February 6th 2025
Article

Radiotherapy plus camrelizumab and platinum-doublet chemotherapy showed manageable toxicity in untreated non–small cell lung cancer with brain metastases.

Updated Results Show THIO/Cemiplimab Improves Median OS in Advanced NSCLC

Updated Results Show THIO/Cemiplimab Improves Median OS in Advanced NSCLC

Tim Cortese
February 5th 2025
Article

6-thio-2’-deoxyguanosine sequenced plus cemiplimab elicited an OS of 16.9 months in the third-line setting for patients with advanced non–small cell lung cancer.